恒瑞医疗 网址: www.hrmedical.com.cn

专业文献

callispheres®载药微球治疗中国肝细胞肝癌的疗效及安全性分析-ag捕鱼平台

文字: 2018-6-28    浏览次数:931    

background:this study aimed to investigate the efficacy and safety of drug eluting beads transarterial chemoembolization(deb-tace) treatment by callispheres® in chinese patients with hepatocellular carcinoma (hcc) as well as the predicting factors for response.

背景:本研究旨在探讨callispheres®载药微球治疗治疗中国肝细胞癌(hcc)的疗效和安全性,并探讨影响疗效的因素。


methods:99 patients with hcc were consecutively enrolled in this study. all participants were treated by callispheres®deb-tace. clinical response was evaluated according to modified response evaluation criteria in solid tumors (mrecist) criteria. common terminology criteria for adverse events (ctcae) was used to assess the adverse events and liver dysfunction during and after the operation.

方法:99例hcc患者连续入选本研究,所有参与者均使用callispheres®载药微球行deb-tace治疗。根据改良的实体瘤(mrecist)疗效评价标准评价临床疗效。采用常见的不良事件术语标准(ctcae)来评估手术期间和术后的不良反应和肝功能障碍。


results:post treatment, 16 patients (16.2%)achieved cr and 59 (59.6%) achieved pr, the orr was 75.8%.subgroup analysis showed that patients with higher bclc stage were of worse cr and orr rates, and the cr as well as orr between patients with ctace history and patients without ctacehistory were similar. univariate logistic regression analysis displayed that number of nodules > 3, higher bclc stage and previous ctace might be correlated with worse orr but with no statistical significance. as to liver function, ctcae grades of laboratory indexes for liver function were increased at 1 week compared to baseline and recovered to the baseline grades at 1–3 months post operation. besides,most of the common adverse events were light and moderate in our study.

结果:deb-tace术后,16例(16.2%)患者达到cr和59例(59.6%)患者达到pr,orr为75.8%,亚组分析显示,bclc分期较高的患者cr和orr的发生率较低,有ctace病史患者与无ctace病史患者的cr及orr相似。单因素logistic回归分析显示,结节数>3,较高的bclc分期和既往的ctace治疗史可能与较差的orr相关,但无统计学意义。肝功能方面,术后1周肝功能实验室指标ctcae评分较术前升高,术后1~3个月恢复至基线,且多数常见不良事件为轻、中度。

 

conclusions: in conclusion, deb-tace by callispheres® was efficient and well tolerated in chinese hcc patients, and bclc stage, number of nodules and ctace historywere possibly correlated with treatment response.

结论:中国肝细胞肝癌使用callispheres®载药微球行deb-tace治疗安全有效,耐受性好。bclc分期、结节数目、ctace病史可能与治疗效果相关。